E-5842: A new potent and preferential sigma ligand. Preclinical pharmacological profile

CNS Drug Reviews

Volumn 4, Issue 3, 1998, Pages 201-224

  Guitart, X ^a   Codony, X ^a   Ballarin M ^a   Dordal, A ^a   Farre A J ^a  

^a Laboratorios Dr Esteve SA   (Spain)

Author keywords

Antipsychotic; E 5824; Schizophrenia; Sigma receptor

Indexed keywords

4 (4 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 [4 (1,2,4 TRIAZOL 1 YL)BUTYL]PYRIDINE; APOMORPHINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LIGAND; N ALLYLNORMETAZOCINE; NEUROLEPTIC AGENT; RISPERIDONE; SIGMA 1 OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AVOIDANCE BEHAVIOR; BINDING AFFINITY; CONTROLLED STUDY; DOPAMINE RECEPTOR BLOCKING; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; EXTRAPYRAMIDAL SYMPTOM; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEGATIVE SYNDROME; NONHUMAN; ORAL DRUG ADMINISTRATION; PROLACTIN RELEASE; RECEPTOR SENSITIVITY; REVIEW; SCHIZOPHRENIA; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032442582     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1998.tb00065.x     Document Type: Review

References (120)

1. 3H]mepyramine from peripheral vs central nervous system receptors by loratidine, a non-sedating antihistamine. Eur J Pharmacol 1986;127:153-155.
2. Akunne HC, Whetzel SZ, Wiley JN, et al. The pharmacology of the novel and selective sigma ligand, PD 144,418. Neuropharmacology 1997;36:51-62.
3. Andreasen NC, Flaum M, Swayze VW, Tyrrell G, Arndt S. Positive and negative symptoms in schizophrenia: A critical reappraisal. Arch Gen Psychiatry 1990;47:615-621.
4. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: Inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 1982;51:321-329.
5. 3H]YM-0951-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics. Eur J Pharmacol 1993;237:183-89.
6. Baldessarini RJ, Tarsey D. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic compounds. Annu Rev Neurosci 1980;3:23-41.
7. Bartoszyk GD, Bender HM, Hellman J, Schnorr C, Seyfred CA. EMD 57445: A selective sigma receptor ligand with the profile of an atypical neuroleptic. CNS Drug Rev 1996;2:175-194.
8. Beatty WW, Jocic Z, Monson N, Stanton RD. Memory and frontal lobe dysfunction in schizophrenia and schizoaffective disorder. J Nerv Ment Dis 1993;181:448-453.
9. Beck CH. Acute treatment with antidepressant drugs selectively increases the expression of c-fos in the rat brain. J Psychiatry Neurosci 1995;20:25-32.
10. Beninger RJ, D'Amico CM, Ranaldi R. Microinjections of flupenthixol into the caudate putamen of rats produce intrasession declines in food-rewarded operant responding. Pharmacol Biochem Behav 1993;45:343-350.
11. Ben-Jonathan N. Dopamine, a prolactin-inhibiting hormone. Endocrine Rev 1985;6:564-589.
12. Benvenga MJ, Leander JD. Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons. Psychopharmacology 1995;119:133-138.
13. Braff DL, Grillon C, Geyer M. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 1992;49:206-215.
14. 2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis: An open dose-finding study. Schizophr Res 1989;2:411-415.
15. 10 mesolimbic system by the σ-receptor agonist (+)SKF 10,047 can be blocked by rimcazole, a novel putative antipsychotic. Eur J Pharmacol 1988;154:53-57.
16. Ceulemans DLS, Gelders YG, Hoppenbrouwers M-LJA, Reyntjens AJM, Janssen PAJ. Effect of serotonin antagonism in schizophrenia: A pilot study with setoperone. Psychopharmacology 1985;85:329-332.
17. Clow A, Theodorou A, Jenner P, Marsden CD. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Eur J Pharmacol 1980;63:145-157.
18. 2 adrenoreceptors. Br J Pharmacol 1989;101:285-290.
19. Cook L, Tam SW, Rohrbach KW. DuP 734 [1-(cyclopropylmethyl-4-(2′(4″-fluorophenyl)-2′-oxoethyl) piperidine Hbr], a potential antipsychotic agent: Preclinical behavioral effects. J Pharmacol Exp Ther 1992;263:1159-1166.
20. Corbett R, Hartman H, Kerman LL, et al. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav 1993;45:9-17.
21. Costall B, Jones BJ, Kelly, Naylor RJ, Tomkins DM. Exploration of mice in a black and white test box: Validation as a model of anxiety. Pharmacol Biochem Behav 1989;32:777-785.
22. Costall B, Domeney AM, Kelly ME, Naylor RJ, Tomkins DM. Actions of ORG 5222 as a novel psychotropic agent. Pharmacol Biochem Behav 1990;35:607-615.
23. Dahmen N, Fehr C, Reuss S, Hiemke C. Stimulation of immediate early gene expression by desipramine in rat brain. Biol Psychiatry 1997;42:317-323.
24. Degan JF, Cook LA. A study of the antimescaline properties of CNS active agents in mice. J Pharmacol Exp Ther 1958;122:17A.
25. 3H](+)-pentazocine to sigma recognition sites in guinea pig brain. Eur J Pharmacol 1992;227:371-378.
26. Den Boer JA, Ravelli DP, Huisman J, Ohrvik J, Verhoeven WMA, Westenberg HGM. Double, blind comparative study of remoxipride and haloperidol in acute schizophrenic patients. Psychopharmacology 1990;102:76-84.
27. DeMaio D. Clozapine, a novel major tranquilizer. Arzneim Forsch 1972;22:919-923.
28. Deutch AY, Duman RS. The effect of antipsychotic drugs on prefrontal cortical Fos expression: Cellular localization and pharmacological characterization. Neuroscience 1995;70:377-389.
29. Deutch AY, Lee MC, Iadarola MJ. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 1992;3:332-341.
30. 2 dopamine-receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience 1990;37:287-292.
31. Eveden JL, Ryan CN. Behavioral responses to psychomotor stimulant compounds: Localization in the central nervous system. In: Balfour DJK, ed. Psychotropic compounds of abuse. New York: Pergamon Press, 1990:1-21.
32. 2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 1994;55(Suppl B):67-69.
33. Fenton HM, Liebman JM. Self-stimulation response decrement patterns differentiate clonidine, baclofen, and dopamine antagonists from drugs causing performance deficit. Pharmacol Biochem Behav 1982;17:1207-1212.
34. Ferris CD, Hirsch DJ, Brooks BP, Snyder SH. σ Receptors: From molecule to man. J Neurochem 1991;57:729-737.
35. Ferris RM, Tang FLM, Chang K-J, Russel A. Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brain. Life Sci 1986;38:2329-2337.
36. Fink-Jensen A, Kristensen P. Effects of typical and atypical neuroleptics on Fos protein expression in rat forebrain. Neurosci Lett 1994;182:115-118.
37. Florijn WJ, Tarazi FI, Creese I. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther 7997;280:561-569.
38. Fowler SC. Neuroleptics produce within-session response decrements: Facts and theories. Drug Dev Res 1990;20:101-116.
39. Friboes RM, Murck H, Wiedemann K, Holsboer F, Steiger A. Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology 1997:132:82-88.
40. 1C subtypes. Biochem Biophys Res Comm 1992;186:760-767.
41. Gelders YG. Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiat 1989;155(Suppl 5):33-36.
42. Gerlach M. New antipsychotics. Classification, efficacy, and adverse effects. Schizophr Bull 1991;17:289-09.
43. Geyer MA, Swerdlow NR, Mansbach RS, Braff DL. Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull 1990;25:485-489.
44. Gudelsky GA, Nash JF, Berry SA, Meltzer HY. Basic biology of clozapine: electrophysiological and neuroendocrinological studies. Psychopharmacology 1989;99:513-517.
45. Guitart X, Ballarin M, Carceller A, et al. Pharmacological profile of E-5842, a sigma receptor ligand with atypical antipsychotic activity in animal models. Soc Neurosci Abstr 1997;23:530.
46. Hall H, Sällemark M, Jerning E. Effects of remoxipride and related new substituted salicylamides on rat brain receptors. Acta Pharmacol Toxicol 1986;58:61-70.
47. 3H]8-Hydroxy-2(di-n-propylamino)-tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain. J Neurochem 1985;44:1685-1696.
48. Halperin R, Guerin J Jr, Davis KL. Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics. Psychopharmacology 1989:98:386-391.
49. 3H]ifenprodil binding to σ receptors in rat brain. Eur J Pharmacol 1993;236:159-163.
50. Hellewell SB, Bowen WD. A sigma-like binding site in rat pheochromocytoma and (PC 12) cells: Decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res 1990;527:244-253.
51. Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic compounds with extrapyramidal side effects liability. Psychopharmacology 1995;120:128-133.
52. 2 receptor sites: Allosteric interactions between sigma, and monoamine oxidase (MAO) in the brain. In: Kamena JM, Domino EF, eds. Multiple sigma and PCP receptor ligands: Mechanism for neuromodulation and neuroprotection. Ann Arbor, MI: NPP Books, 1992:241-255.
53. Jackson DM, Ryan C, Evenden J, Mohell N. Preclinical findings with antipsychotic agents: What makes them atypical? Acta Psychiatr Scand 1994;89(Suppl 380):41-48.
54. Jenner P, Marsden CD. Chronic pharmacological manipulation of dopamine receptors in brain. Neuropharmacology 1987;26:931-940.
55. Kane J, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative Study group. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-796.
56. Karbon EW, Abreu ME, Erickson RH, et al. NPC 16377, a potent and selective σ ligand. I. Receptor binding, neurochemical and neuroendocrine profile. J Pharmacol Exp Ther 1993:265:866-875.
57. Kehne JH, Padich RA, McClosky TC, Taylor VL, Schmidt CJ. 5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light pre-pulse inhibition in Wistar rats. Psychopharmacology 1996;124:95-106.
58. 3H]raclopride. Biochem Pharmacol 1985;34:2251-2259.
59. Kuribara H, Tadokoro S. Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses. Pharmacol Biochem Behav 1981;14:181-192.
60. Largent BL, Wilkstrom H, Snowman AM, Snyder SH. Novel antipsychotic drugs share high affinity for σ receptors. Eur J Pharmacol 1988:155:345-347.
61. Leblanc H, Lachelin GCL, Abu-Fadil S, Yen SSC. Effects of dopamine infusion on pituitary secretion in humans. J Clin Endocrinol Metab 1976;43:668-674.
62. Leong DA, Frawley LS, Neil JD. Neuroendocrine control of prolactin secretion. Annu Rev Physiol 1983;45:109-127.
63. 3H]hydroxy-N,N-di-n-propyl-2 aminotetratlin. Proc Natl Acad Sci USA 1992;89:8155-8159.
64. 3H]ligand for serotonin-2 receptor binding sites. Mol Pharmacol 1982;21:301-314.
65. Maj J, Rogóz Z, Skuza G, Mazela H. Neuropharmacological profile of EMD 57445, a σ-receptor ligand with potential antipsychotic activity. Eur J Pharmacol 1996;315:235-243.
66. Mansbach RS, Geyer MA, Braff DL. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology 1988;94:507-514.
67. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine and nalorphine-like drugs in the non-dependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976:197:517-532.
68. Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: A review. Schizophr Bull 1976;2:19-76.
69. Merchant KM, Dorsa DM. Differential induction of neurotensin and c-fos gene expression by typical vs. atypical antipsychotics. Proc Natl Acad Sci USA 1993;90:3447-3451.
70. 3 receptors. Cerebral Cortex 1996;6:561-570.
71. 1A subtype in rat submaxillary gland. Br J Pharmacol 1989a;98:883-889.
72. 2B-adrenoreceptor subtypes. Br J Pharmacol 1989b;98:890-897.
73. Moghaddam B, Bunney BS. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study. J Neurochem 1990;54:1755-1760.
74. 2 receptor activation. Psychopharmacology 1988;94:263-266.
75. Morgan JI, Curran T. Stimulus-transcription coupling in the nervous system: Involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci 1991;14:421-451.
76. Morinobu S, Strausbaugh H, Terwilliger R, Duman RS. Regulation of c-fos and NGF1-A by antidepressant treatments. Synapse 1997;25:313-320.
77. 2 dopamine-receptor blockade with raclopride on intracranial self-stimulation and food-reinforced operant behavior. Psychopharmacology 1989;98:330-333.
78. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 1994;115:147-156.
79. 2 dopamine-receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology 1992;106:433-438.
80. O'Dell SJ, La Hoste GJ, Widmark CB, Shapiro RM, Potkin SG, Marshall JF. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 1990;6:146-153.
81. Ögren SO, Hall H, Köhler C, et al. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 1984;102:459-474.
82. 2A receptor antagonist, in rats. Br J Pharmacol 1997:121:515-525.
83. Pugsley TA, Davis MD, Akunne HC, et al. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects. J Pharmacol Exp Ther 1995:274:898-911.
84. Quirion R, Chicheportiche PC, Contreras KM, et al. Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Neurosci 1987;10:444-446.
85. Quirion R, Bowen WD, Itzhak Y, et al. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 1992;13:85-86.
86. Rasmussen K, Gates MR, Burger JE, Czachura JF. The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY 288,513, blocks apomorphine-induced disruption of pre-pulse inhibition. Neurosci Lett 1997;222:61-64.
87. Rigdon GC, Viik K. Prepulse inhibition as a screening test for potential antipsychotics. Drug Dev Res 1991;23:91-99.
88. Robertson GS, Fibiger HC. Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience 1992;46:315-329.
89. Robertson GS, Matsumara H, Fibiger HC. Induction of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994;271:1058-1066.
90. Rupniak NMJ, Mann S, Hall MD, et al. Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat. Psychopharmacology 1984;4:503-511.
91. Sagar SM, Sharp FR, Curran T. Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science 1988;240:1328-1331.
92. Sanger DJ, Perrault G. Effects of typical and atypical antipsychotic drugs on response decrement patterns in rate. J Pharmacol Exp Ther 1995;272:706-713.
93. 2A-receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 1995;273:273-279.
94. Seeman P. Brain dopamine receptors. Pharmacol Rev 1980;32:229-313.
95. 2 receptors following long-term treatment with roxindole. Eur J Pharmacol 1994;257:67-72.
96. Shader RI, Mascio A. Psychotropic drug side effects: Chemical and theoretical perspectives. Baltimore: Williams and Wilkins Co., 1970.
97. Sipes TA, Geyer MA. Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology 1994;33:441-448.
98. 2 receptor antagonist MDL 100,907 as a putative atypical antipsychotic: Behavioral, electrophysiological, and neurochemical studies. J Pharmacol Exp Ther 1993;266:684-691.
99. Sovner R, Pamell-Sovner N. Use of buspirone in the treatment of schizophrenia. J Clin Psychopharmacol 1989:9:61-62.
100. Steinfels GF, Tarn SW. Selective α-receptor agonists and antagonists affect dopamine neuronal activity. Eur J Pharmacol 1989;163:167-170.
101. Steinfels GF, Tarn SW, Cook L. Electrophysiological effects of selective σ-receptor agonists, antagonists, and the selective phencyclidine-receptor agonist MK-801 on midbrain dopamine neurons. Neuropsychopharmacology 1989;2:201-208.
102. 3H]SKF 10,047 to etorphine-inaccessible sites in guinea pig brain. J Pharmacol Exp Ther 1982;223:284-290.
103. Su TP. σ Receptors: Putative links between nervous, endocrine and immune systems. Eur J Biochem 1991;200:633-642.
104. Swerdlow NR, Caine SB, Braff DL, Geyer MA. Neural substrates of sensorimotor gating of the startle reflex: A review of recent findings and their implications. J Psychopharmacol 1992;6:176-190.
105. Swerdlow NR, Braff DL, Taaid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994;1:139-154.
106. Szewczak MR, Corbett R, Rush DK, et al. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J Pharmacol Exp Ther 1995;274:1404-413.
107. Tam SW. Naloxone-inaccessible sigma receptor in rat central nervous system. Proc Natl Acad Sci USA 1983;80:6703-6707.
108. 3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA 1984;81:5618-5621.
109. 2 receptor antagonist; receptor-binding, electrophysiological and neuropharmacological profiles. J Pharmacol Exp Ther 1992;263:1167-1174.
110. Taylor DP, Dekleva J. BMY 14802: A potential antipsychotic agent that selectively binds to sigma receptors. In: Domino EF and Karnenka JM, eds. Sigma and phencyclidine-like compounds as molecular-probes in biology. Ann Arbor: NPP Books, 1988:345-355.
111. Taylor DP, Eison MS, Moon SL, Yocca FD. BMY 14802: A potential antipsychotic with selective affinity for σ-binding sites. In: Tamminga CA, Schulz SC, eds. Schizophrenia research. New York: Raven Press, 1991:307-316.
112. Titeler M. Multiple dopamine receptors. New York: Marcel Dekker Inc., 1983.
113. Ungerstedt U. Measurement of neurotransmitter release by intracranial dialysis. In: Marsden CA, ed. Measurement of neurotransmitter release in vivo. New York: John Wiley & Sons, 1984:81-105.
114. Walker JM, Brown WD, Walker FO, Matsumoto RR, DeCosta B, Rice KC. Sigma receptors: Biology and function. Pharmacol Rev 1990;42:355-402.
115. Weber E, Sonders M, Quarum M, Mclean S, Pou S, Keana JFW. 1,3-di(2-[5-3H]tolyl)guanidine: A selective ligand that labels s-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc Natl Acad Sci USA 1986;83:8784-8788.
116. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-669.
117. Weissman AD, Su TP, Hedreen JC, London DE. Sigma receptors in post-mortem human brains. J Pharmacol Exp Ther 1988;247:29-33.
118. Weissman AD, Casanova MF, Kleinman JE, London ED, De Souza EB. Selective loss of cerebral cortical sigma, but not PCP-binding sites in schizophrenia. Biol Psychiatry 1991;29:41-54.
119. Willner P, Philips G, Muscat R, Hood P. Behavioural tests of the dopamine depletion hypothesis of neuroleptic-induced response decrement. Psychopharmacology 1992;106:543-549.
120. Zhang J, Chiodo LA, Wettstein JG, Junien JL, Freeman AS. Acute effects of sigma ligands on the electrophysiological activity of rat nigrostriatal and mesoaccumbal dopaminergic neurons. Synapse 1992;11:267-278.